Sex differences in the transmission, prevention, and disease manifestations of sexually transmitted diseases

Archives of Dermatology

Volumn 142, Issue 3, 2006, Pages 365-370

  Madkan, Vandana K ^a,d   Giancola, Angela A ^b   Sra, Karan K ^c   Tyring, Stephen K ^b  

^a CENTER FOR CLINICAL STUDIES   (United States)

^b University of Texas Health Science Center at Houston   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; HERPES VACCINE; MICROBICIDE; VIRUS VACCINE;

ANUS CANCER; ASEPTIC MENINGITIS; AUTONOMIC NEUROPATHY; BACTERIAL TRANSMISSION; CHLAMYDIASIS; CLINICAL FEATURE; ECTOPIC PREGNANCY; GENITAL ULCER; GONORRHEA; GRANULOMA INGUINALE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHADENITIS; LYMPHOGRANULOMA VENEREUM; NEUROSYPHILIS; PELVIC INFLAMMATORY DISEASE; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; SALPINGITIS; SEX DIFFERENCE; SEXUALLY TRANSMITTED DISEASE; SKIN INFECTION; SOCIAL BEHAVIOR; TRICHOMONIASIS; ULCUS MOLLE; UTERINE CERVIX CANCER; VAGINA DISCHARGE; VAGINITIS; VERRUCA VULGARIS; VIRUS INFECTION; WART VIRUS;

FEMALE; HIV INFECTIONS; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEX FACTORS; SEXUALLY TRANSMITTED DISEASES;

EID: 33645106604     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.3.365     Document Type: Review

References (61)

1. Brown TJ, Yen-Moore A, Tyring SK. An overview of sexually transmitted diseases: part I. J Am Acad Dermatol. 1999;41:511-532.
2. Wu JJ, Huang DB, Pang KR, Tyring SK. Selected sexually transmitted diseases and their relationship to HIV. Clin Dermatol. 2004;22:499-508.
3. Czelusta A, Yen-Moore A, Van der Straten M, Carrasco D, Tyring SK. An overview of sexually transmitted diseases, part III: sexually transmitted diseases in HIV-infected patients. J Am Acad Dermatol. 2000;43:409-432.
4. Jean-Robert RM. The woman's status and condom use in Cameroon. Afr J Reprod Health. 2003;7:74-88.
5. Quinn TC, Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science. 2005;308:1582-1583.
6. van Ginkel FW, Nguyen HH, McGhee JR. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infect Dis. 2000;6:123-132.
7. Ray SC, Quinn TC. Sex and the genetic diversity of HIV-1. Nat Med. 2000;6:23-25.
8. Stary A. Sexually transmitted diseases. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. New Haven, Conn: Mosby; 2003:1271-1294.
9. Bushnell AC. Lymphogranuloma venereum. Available at: http://www.emedicine .com/EMERG/topic304.htm. Accessed November 22, 2005.
10. Boucher KW. Granuloma inguinale (donovanosis). Available at: http://www .emedicine.com/derm/topic172.htm#targetA. Accessed November 22, 2005.
11. Division of STD Prevention, Centers for Disease Control and Prevention. Genital herpes: CDC fact sheet. Available at: http://www.cdc.gov/std/Herpes /STDFact-Herpes.htm. Accessed November 3, 2005.
12. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347:1652-1661.
13. Bernstein DI, Aoki FY, Tyring SK, et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis. 2005;40:1271-1281.
14. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA. 2001;285:3100-3106.
15. Centers for Disease Control and Prevention. Male latex condoms and sexually transmitted diseases. Available at: http://www.cdc.gov/nchstp/od/latex. htm. Accessed November 15, 2005.
16. McNamee K. The female condom. Aust Fam Physician. 2000;29:555-557.
17. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983;98:958-972.
18. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis. 1998;26:541-553.
19. Sacks SL, Griffiths PD, Corey L, et al. HSV-2 transmission. Antiviral Res. 2004;63(suppl 1):S27-S35.
20. Bourne N, Zaneveld LJ, Ward JA, Ireland JP, Stanberry LR. Poly(sodium 4-styrene sulfonate): evaluation of a topical microbicide gel against herpes simplex virus type 2 and Chlamydia trachomatis infections in mice. Clin Microbiol Infect. 2003;9:816-822.
21. Division of STD Prevention, Centers for Disease Control and Prevention. Genital HPV infection: CDC fact sheet. Available at: http://www.cdc.gov/std/HPV /STDFact-HPV.htm. Accessed November 3, 2005.
22. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004;101:281-288.
23. Bayo S, Bosch FX, de Sanjose S, et al. Risk factors of invasive cervical cancer in Mali. Int J Epidemiol. 2002;31:202-209.
24. Tseng HF, Morgenstern H, Mack TM, Peters RK. Risk factors for anal cancer: results of a population-based case-control study. Cancer Causes Control. 2003;14:837-846.
25. Frisch M, Glimelius B, Wohlfahrt J, Adami HO, Melbye M. Tobacco smoking as a risk factor in anal carcinoma: an antiestrogenic mechanism? J Natl Cancer Inst. 1999;91:708-715.
26. Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346:1105-1112.
27. Christensen ND. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2005;10:5-19.
28. Roden R, Wu TC. Preventative and therapeutic vaccines for cervical cancer. Expert Rev Vaccines. 2003;2:495-516.
29. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
30. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765.
31. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278.
32. Centers for Disease Control and Prevention. Chlamydia. Available at: http://www .cdc.gov/std/stats/chlamydia.htm. Accessed November 11, 2005.
33. Division of STD Prevention, Centers for Disease Control and Prevention. Chlamydia: CDC fact sheet. Available at: http://www.cdc.gov/std/Chlamydia /STDFact-Chlamydia.htm. Accessed November 8, 2005.
34. Holmes KK, Counts GW, Beaty HN. Disseminated gonococcal infection. Ann Intern Med. 1971;74:979-993.
35. Masi AT, Eisenstein BI. Disseminated gonococcal infection (DGI) and gonococcal arthritis (GCA), II: clinical manifestations, diagnosis, complications, treatment, and prevention. Semin Arthritis Rheum. 1981;10:173-197.
36. O'Brien JP, Goldenberg DL, Rice PA. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine (Baltimore). 1983;62:395-406.
37. Handsfield HH. Disseminated gonococcal infection. Clin Obstet Gynecol. 1975;18:131-142.
38. Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis. 1992;19:185-192.
39. Wong T, Singh A, Mann J, Hansen L, McMahon S. Gender differences in bacterial STIs in Canada. BMC Womens Health. 2004;4(suppl 1):S26.
40. Division of STD Prevention, Centers for Disease Control and Prevention. Trichomoniasis: CDC fact sheet. Available at: http://www.cdc.gov/std/Trichomonas /STDFact-Trichomoniasis.htm. Accessed November 8, 2005.
41. World Health Organization. Number of women living with HIV increases in each region of the world. Available at: http://www.who.int/3by5/news34/en/. Accessed November 3, 2005.
42. Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med. 2003;9:847-852.
43. UNAIDS. Women, girls, HIV, and AIDS. Available at: http://www.unaids.org /wad2004/index.html. Accessed November 8, 2005.
44. Abner SR, Guenthner PC, Guarner J, et al. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis. 2005;192:1545-1556.
45. Doria-Rose NA, Learn GH, Rodrigo AG, et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol. 2005;79:11 214-11 224.
46. Wang S, Arthos J, Lawrence JM, et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol. 2005;79:7933-7937.
47. Morris CB, Cheng E, Thanawastien A, Cardenas-Freytag L, Clements JD. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G). Vaccine. 2000;18:1944-1951.
48. Latif AS, Katzenstein DA, Bassett MT, Houston S, Emmanuel JC, Marowa E. Genital ulcers and transmission of HIV among couples in Zimbabwe. AIDS. 1989;3:519-523.
49. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35:435-445.
50. The National Institute of Allergy and Infectious Diseases. Gonorrhea. Available at: http://www.niaid.nih.gov/factsheets/stdgon.htm. Accessed November 15, 2005.
51. The National Institute of Allergy and Infectious Diseases. HIV infection in adolescents and young adults in the US. Available at: http://www.niaid.nih. gov /factsheets/hivadolescent.htm. Accessed November 17, 2005.
52. Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev. 2004;17:794-803.
53. Pinto AP, Baggio HC, Guedes GB. Sexually-transmitted viral diseases in women: clinical and epidemiological aspects and advances in laboratory diagnosis. Braz J Infect Dis. 2005;9:241-250.
54. Newell ML. Prevention of mother-to-child transmission of HIV: challenges for the current decade. Bull World Health Organ. 2001;79:1138-1144.
55. Division of STD Prevention, Centers for Disease Control and Prevention. Gonorrhea: CDC fact sheet. Available at: http://www.cdc.gov/std/Gonorrhea /STDFact-gonorrhea.htm. Accessed November 8, 2005.
56. Go VF, Quan VM, Chung A, Zenilman J, Hanh VT, Celentano D. Gender gaps, gender traps: sexual identity and vulnerability to sexually transmitted diseases among women in Vietnam. Soc Sci Med. 2002;55:467-481.
57. Voeten HA, O'Hara HB, Kusimba J, et al. Gender differences in health care-seeking behavior for sexually transmitted diseases: a population-based study in Nairobi, Kenya. Sex Transm Dis. 2004;31:265-272.
58. Garcia-Sanchez I. Gender differences in HIV/AIDS. Gac Sanit. 2004;18:47-54.
59. Divisions of HIV/AIDS Prevention, Centers for Disease Control and Prevention. HIV/AIDS among women. Available at: http://www.cdc.gov/hiv/pubs/ facts/women .htm. Accessed November 8, 2005.
60. Wendt SJ, Solomon LJ. Barriers to condom use among heterosexual male and female college students. J Am Coll Health. 1995;44:105-110.
61. Leland NL, Barth RP. Gender differences in knowledge, intentions, and behaviors concerning pregnancy and sexually transmitted disease prevention among adolescents. J Adolesc Health. 1992;13:589-599.